InsiderTrades.com logo
First JFK… next Elon?
From Porter & Company   |   Ad
Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.
I share with you in this special investigative documentary.
William Richard White net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

William White Biography and Net Worth

CFO of Akero Therapeutics
Bill White is the Chief Financial Officer and Head of Corporate Development at Akero Therapeutics. Prior to joining Akero, Bill spent 18 years as a life-science-focused investment banker. He was most recently Head of U.S. Life Sciences Investment Banking at Deutsche Bank, and previously worked at Goldman Sachs and Citigroup. Prior to his time on Wall Street, Bill was an attorney at Sullivan & Cromwell, and a Law Clerk to the Honorable Kimba M. Wood of the Southern District of New York. He holds an AB from Princeton, MPP from Harvard, and a JD from Columbia.

What is William Richard White's net worth?

The estimated net worth of William Richard White is at least $1.12 million as of December 10th, 2024. Mr. White owns 38,335 shares of Akero Therapeutics stock worth more than $1,124,749 as of December 21st. This net worth evaluation does not reflect any other investments that Mr. White may own. Additionally, Mr. White receives a salary of $678,060.00 as CFO at Akero Therapeutics. Learn More about William Richard White's net worth.

How old is William Richard White?

Mr. White is currently 51 years old. There are 6 older executives and no younger executives at Akero Therapeutics. The oldest executive at Akero Therapeutics is Dr. Timothy Rolph, Co-Founder & Chief Scientific Officer, who is 70 years old. Learn More on William Richard White's age.

What is William Richard White's salary?

As the CFO of Akero Therapeutics, Inc., Mr. White earns $678,060.00 per year. There are 2 executives that earn more than Mr. White. The highest earning executive at Akero Therapeutics is Dr. Andrew Cheng M.D., Ph.D., President, CEO & Director, who commands a salary of $1,040,000.00 per year. Learn More on William Richard White's salary.

How do I contact William Richard White?

The corporate mailing address for Mr. White and other Akero Therapeutics executives is 170 HARBOR WAY, SOUTH SAN FRANCISCO CA, 94080. Akero Therapeutics can also be reached via phone at (650) 487-6488 and via email at [email protected]. Learn More on William Richard White's contact information.

Has William Richard White been buying or selling shares of Akero Therapeutics?

Over the course of the past ninety days, William Richard White has sold $86,735.43 in Akero Therapeutics stock. Most recently, William Richard White sold 2,817 shares of the business's stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $30.79, for a transaction totalling $86,735.43. Following the completion of the sale, the chief financial officer now directly owns 38,335 shares of the company's stock, valued at $1,180,334.65. Learn More on William Richard White's trading history.

Who are Akero Therapeutics' active insiders?

Akero Therapeutics' insider roster includes Kevin Bitterman (Director), Andrew Cheng (CEO), William White (CFO), Catriona Yale (Insider), and Jonathan Young (COO). Learn More on Akero Therapeutics' active insiders.

Are insiders buying or selling shares of Akero Therapeutics?

During the last twelve months, insiders at the sold shares 44 times. They sold a total of 818,039 shares worth more than $24,252,058.49. The most recent insider tranaction occured on December, 16th when VP Patrick Lamy sold 1,000 shares worth more than $29,130.00. Insiders at Akero Therapeutics own 7.9% of the company. Learn More about insider trades at Akero Therapeutics.

Information on this page was last updated on 12/16/2024.

William Richard White Insider Trading History at Akero Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/10/2024Sell2,817$30.79$86,735.4338,335View SEC Filing Icon  
9/10/2024Sell639$26.18$16,729.0241,152View SEC Filing Icon  
8/26/2024Sell75,159$27.21$2,045,076.3941,791View SEC Filing Icon  
7/24/2024Sell139,083$26.98$3,752,459.3441,791View SEC Filing Icon  
7/16/2024Sell34,811$28.04$976,100.4441,791View SEC Filing Icon  
6/11/2024Sell2,831$22.64$64,093.8446,799View SEC Filing Icon  
12/14/2023Sell611$20.76$12,684.3650,354View SEC Filing Icon  
9/13/2023Sell632$50.34$31,814.8818,468View SEC Filing Icon  
6/20/2023Sell20,777$55.00$1,142,735.0019,100View SEC Filing Icon  
6/13/2023Sell606$55.16$33,426.9622,377View SEC Filing Icon  
12/28/2022Sell999$49.76$49,710.2423,624View SEC Filing Icon  
10/13/2022Sell20,000$39.82$796,400.004,429View SEC Filing Icon  
9/13/2022Sell32,500$27.03$878,475.004,429View SEC Filing Icon  
1/14/2022Sell9,700$22.03$213,691.00View SEC Filing Icon  
12/21/2021Sell100$22.00$2,200.00View SEC Filing Icon  
12/17/2021Sell3,200$22.04$70,528.00View SEC Filing Icon  
8/2/2021Sell4,441$22.03$97,835.237,718View SEC Filing Icon  
7/6/2021Sell6,500$24.52$159,380.009,777View SEC Filing Icon  
4/1/2021Sell50,000$28.64$1,432,000.0052,270View SEC Filing Icon  
See Full Table

William Richard White Buying and Selling Activity at Akero Therapeutics

This chart shows William Richard White's buying and selling at Akero Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Akero Therapeutics Company Overview

Akero Therapeutics logo
Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $29.34
Low: $28.09
High: $29.77

50 Day Range

MA: $30.89
Low: $28.09
High: $35.28

2 Week Range

Now: $29.34
Low: $15.32
High: $37.00

Volume

1,559,947 shs

Average Volume

844,736 shs

Market Capitalization

$2.05 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
First JFK… next Elon?
From Porter & Company   |   Ad
Today, I have another controversial prediction. One which I will take no pleasure in seeing come true. See, even with President Trump returning as the leader of our free country, I believe Elon Musk is in mortal danger.
I share with you in this special investigative documentary.